A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
Status:
Recruiting
Trial end date:
2025-05-08
Target enrollment:
Participant gender:
Summary
This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled,
dose-ranging, 12-week study. It is designed to assess the therapeutic dose, efficacy, and
safety of treatment with SAR441566 in male and female adults with moderate to severe plaque
psoriasis. Study details include a screening period (4 weeks and not less than 11 days before
Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up)
(2 weeks ± 3 days). The total number of study visits will be 7.